Desloratadine

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H19ClN2
Molecular Weight	310.821
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C4CCNCC4)=C1

InChI

InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N

InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Antagonist 2849		0.87 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Seasonal allergic rhinitis 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8583	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 2001
Perennial allergic rhinitis 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8583	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 2001
Chronic idiopathic urticaria 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8583	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 2001

C_max

Value	Dose	Co-administered	Analyte	Population
4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
56.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
27 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf	unhealthy, 2-11 years Health Status: unhealthy Age Group: 2-11 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf	Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Abdominal pain (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf

AEs

AE	Significance	Dose	Population
Abdominal pain	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf	unhealthy, 2-11 years Health Status: unhealthy Age Group: 2-11 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf
Somnolence	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf	unhealthy, 2-11 years Health Status: unhealthy Age Group: 2-11 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 CYP2C19 2057 CYP2B6 926 CYP3A4/5 296 UGT1A1 246 UGT1A3 89 UGT1A4 98 UGT1A6 136 UGT1A9 148 UGT2B7 197 UGT2B10 31 UGT2B15 84 UGT2B17 31 UGT1A7 23 UGT1A8 37 UGT1A10 37 UGT2B4 23 P-gp 1741	CYP1A2 1197 CYP2B6 776 CYP1A1 389 CYP2C19 1119 UGT2B10 131 P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C19 2141	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C8 1117	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C9 2497	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
UGT1A1 303	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A3 99	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A4 100	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A6 171	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A7 25	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A8 49	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A9 155	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B15 84	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B7 210	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11454724/	not significant [IC50 43 uM]
UGT2B10 33	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	strong [Ki 1.3 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP3A4/5 357	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
UGT1A10 46	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B17 33	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B4 23	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 389	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely	no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely	no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0	likely	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0
UGT2B10 131	substrate 4014 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/	yes	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/11243504/#:~:text=Preclinical%20studies%20also%20show%20that,in%20preclinical%20and%20clinical%20studies.

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:291342	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:291342
ChemicalBook	CB3462564	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3462564
eMolecules	877481	https://www.emolecules.com/cgi-bin/more?vid=877481
MolPort	MolPort-000-883-875	https://www.molport.com/shop/molecule-link/MolPort-000-883-875
Selleck Chemicals	desloratadine	http://www.selleckchem.com/products/desloratadine.html
ZINC	ZINC000000001261	http://zinc15.docking.org/substances/ZINC000000001261

PubMed

Title	Date	PubMed
Mediator antagonists in the treatment of allergic disease.	2001 Sep-Oct	11715214
Second-generation antihistamines in asthma therapy: is there a protective effect?	2002	14720073
Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion.	2002	14720057
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays.	2002	12391581
Lack of clinically relevant interaction between desloratadine and erythromycin.	2002	12169044
A pharmacokinetic profile of desloratadine in healthy adults, including elderly.	2002	12169042
Desloratadine demonstrates dose proportionality in healthy adults after single doses.	2002	12169040
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].	2002 Aug 5	12162793
The new antihistamines--desloratadine and levocetirizine: a review.	2002 Dec	12851991
Comparative pharmacology of H1 antihistamines: clinical relevance.	2002 Dec 16	12517581
Treatment of allergic rhinitis.	2002 Dec 16	12517578
[The result of neglected or erroneous treatment. Mentally handicapped by hay fever].	2002 Jul 11	12198886
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.	2002 Jun	12063524
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion.	2002 Nov	12452207
Clinical pharmacology of H1-antihistamines in the skin.	2002 Nov	12417888
Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.	2002 Oct	12392387
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.	2002 Oct	12372132
Severe hepatotoxicity after application of desloratadine and fluconazole.	2003	12975558
Desloratadine: an update of its efficacy in the management of allergic disorders.	2003	12962522
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.	2003 Apr	12664016
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men.	2003 Aug	14512130
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.	2003 Aug	12952117
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.	2003 Aug	12924753
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.	2003 Aug 13	12917016
Gateways to clinical trials.	2003 Dec	14735233
Interactions of olopatadine and selected antihistamines with model and natural membranes.	2003 Dec	14704897
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.	2003 Jan 6	12515585
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.	2003 Jul	12946545
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.	2003 Jul	12847492
[Safety of new antihistamines].	2003 Jun	14524292
[Clinical aspects of anti-inflammatory action of antihistamines].	2003 Jun	14524290
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.	2003 Jun	12814463
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.	2003 Jun	12801313
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.	2003 Jun	12757447
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.	2003 Mar	12642846
P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.	2003 Mar	12584158
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].	2003 May 25	12847854
Desloratadine for allergic rhinitis.	2003 Nov 15	14655812
Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias.	2003 Oct	14619900
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis.	2003 Oct	14582817
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.	2003 Oct	14530791
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.	2003 Oct	14520518
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.	2003 Oct	12968983
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.	2003 Oct 25	14552827
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].	2003 Oct 30	14655512
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine.	2004 Apr	15005765
Inhibition of cold urticaria by desloratadine.	2004 Jan	14754651
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.	2004 Jan	14741075
Gateways to clinical trials.	2004 Jan-Feb	14988742
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs.	2004 Mar 10	15019035

Patents

Sample Use Guides

In Vivo Use Guide

Adults and Adolescents 12 Years of Age and Over: take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.

Route of Administration: Oral

In Vitro Use Guide

Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.

Name

Type

Language

CLARINEX-D COMPONENT DESLORATADINE

Preferred Name

English

Desloratadine

Official Name

English

8-Chloro-5,6-dihydro-11-(piperidin-4-ylidene)-11H-benzo[5,6]cyclohepta[1,2-b]pyridine)

Systematic Name

English

DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE RATIOPHARM

Brand Name

English

DENOSIN

Brand Name

English

desloratadine [INN]

Common Name

English

5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-

Systematic Name

English

DASSELTA

Brand Name

English

NSC-759824

Code

English

DESLORATADINE [MART.]

Common Name

English

LORATADINE RELATED COMPOUND A [USP IMPURITY]

Common Name

English

NEOCLARITYN

Brand Name

English

DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE [MI]

Common Name

English

DESLORATADINE [VANDF]

Common Name

English

DESLORATADINE [USP-RS]

Common Name

English

RUPATADINE FUMARATE IMPURITY B [EP IMPURITY]

Common Name

English

DESLORATADINE [USP MONOGRAPH]

Common Name

English

CLARINEX

Brand Name

English

DESCARBOETHOXYLORATADINE

Common Name

English

DESLORATADINE ACTAVIS

Brand Name

English

DESLORATADINE TEVA (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE [ORANGE BOOK]

Common Name

English

OPULIS

Brand Name

English

SCH-34117

Code

English

AZOMYR

Brand Name

English

ALLEX

Brand Name

English

Desloratadine [WHO-DD]

Common Name

English

DESLORATADINE TEVA

Brand Name

English

LORATADINE IMPURITY D [EP IMPURITY]

Common Name

English

AERIUS

Brand Name

English

DESLORATADINE [JAN]

Common Name

English

LORATADINE RELATED COMPOUND A [USP-RS]

Common Name

English

DESLORATADINE [EMA EPAR]

Common Name

English

DESLORATADINE [EP MONOGRAPH]

Common Name

English

DESLORATADINE [USAN]

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

LIVERTOX

NBK548831

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

WHO-VATC

QR06AX27

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

OPULIS (WITHDRAWN: RHINITIS, URTICARIA)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

NCI_THESAURUS

C29578

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

NDF-RT

N0000175587

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

ALLEX(WITHDRAWN: RHINITIS, ALLERGIC, SEASONAL)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

DASSELTA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

AZOMYR (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

WHO-ATC

R06AX27

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

AERINAZE (AUTHORIZED: RHINITIS)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

AERIUS(AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

EMA ASSESSMENT REPORTS

NEOCLARITYN (AUTHORIZED: RHINITIS, URTICARIA)

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

NDF-RT

N0000000190

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

Code System Code Type Description

ChEMBL

CHEMBL1172

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

DRUG BANK

DB00967

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

RS_ITEM_NUM

1370280

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

ALTERNATIVE

MESH

C121345

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

CHEBI

291342

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

INN

7817

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

RXCUI

275635

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

RxNorm

SMS_ID

100000089395

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

EPA CompTox

DTXSID1044196

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

LACTMED

Desloratadine

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

NCI_THESAURUS

C47474

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

NSC

759824

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

PUBCHEM

124087

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

USAN

KK-46

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

DRUG CENTRAL

814

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

FDA UNII

FVF865388R

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

DAILYMED

FVF865388R

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

WIKIPEDIA

Desloratadine

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

RS_ITEM_NUM

1173042

Created by admin on Wed Apr 02 06:53:06 GMT 2025 , Edited by admin on Wed Apr 02 06:53:06 GMT 2025

PRIMARY

IUPHAR

7157

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

MERCK INDEX

m4193

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

Merck Index

EVMPD

SUB01596MIG

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

CAS

100643-71-8

Created by admin on Wed Apr 02 06:53:05 GMT 2025 , Edited by admin on Wed Apr 02 06:53:05 GMT 2025

PRIMARY

ACTIVE MOIETY


					FVF865388R

Desloratadine

METABOLITE (PARENT)


					ZW1TK7TV04

6-HYDROXYDESLORATADINE

METABOLITE (PARENT)


					KE8G39GEF7

5-HYDROXYDESLORATADINE

METABOLITE (PARENT)


					D3KVV9T2MG

3-HYDROXYDESLORATADINE O-GLUCURONIDE

PARENT (METABOLITE ACTIVE)


					7AJO3BO7QN

LORATADINE

SALT/SOLVATE (PARENT)


					WGA590NHUY

DESLORATADINE HEMISULFATE

SALT/SOLVATE (PARENT)


					CZ422FA2AK

DESLORATADINE CITRATE DISODIUM

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11243504Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

CNS Activity

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

C_max

T_1/2

F_unbound

Drug as perpetrator